Form 4: Equillium COO Granted 500K Stock Options

Equillium, Inc.'s Senior Vice President and Chief Operating Officer, Christine Zedelmayer, was granted 500,000 employee stock options with an exercise price of $1.31.

Summary

• Christine Zedelmayer, Senior Vice President and Chief Operating Officer of Equillium, Inc., was granted 500,000 employee stock options.
• The options have an exercise price of $1.31 per share.
• The vesting commencement date for these options is January 7, 2026.
• Twenty-five percent of the shares subject to the option will vest on the first anniversary of the vesting commencement date (January 7, 2027).
• The remaining 75% of the shares will vest in 36 equal monthly installments over the subsequent three years.
• The options are set to expire on January 6, 2036.
• Following this transaction, Christine Zedelmayer beneficially owns 500,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment and incentive for long-term company performance. It is a routine compensation event, not directly tied to immediate financial results, hence a moderately positive score.

Positives

• The grant of 500,000 stock options to a key executive like the COO aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the executive.

Future Outlook

The vesting schedule for the granted options indicates a long-term commitment from the Senior Vice President and COO, with shares vesting over a four-year period starting from January 7, 2026, and the options expiring in 2036.

Industry Context

Executive stock option grants are a standard component of compensation packages in the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key talent by aligning their financial interests with the long-term success and share price performance of the company.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased management incentive and alignment with long-term company performance.
• Employees: May set a precedent or benchmark for executive compensation within the company.

Next Steps

• The first 25% of the granted options will vest on January 7, 2027.
• The remaining 75% of the options will vest in 36 equal monthly installments over the subsequent three years following the first anniversary.

Key Dates

Keywords

Equillium, EQ, stock option, insider transaction, Form 4, Christine Zedelmayer, COO, executive compensation, equity grant